RBC raises Amgen stock price target to $400 on strong quarter
RBC raises Amgen stock price target to $400 on strong quarter Investing.com Canada
Covered in this story
What has happened since
- Amgen is down 1.2% since this was published, 61 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
RBC Capital Markets’s $400 target on $AMGN is on the record and being tracked to Aug 2027 (12-month default), scored on the close that day.
RBC Capital Markets’s track record →Analyst targets on Amgen
- Scotiabank: $403 → $500 by Oct 2027 via AD HOC NEWS
- Scotiabank: $424 → $500 by Sep 2027 · Sector Outperform via GuruFocus
- UBS: $408 → $440 by Aug 2027 · Buy via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 50 stories mentioning Amgen, the earliest published 2 Jul 2026.
Summary aggregated from Investing.com Canada's public RSS feed. The full reporting belongs to Investing.com Canada — please read it on their site.